Danijela Stojanovic

Danijela Stojanovic

Auto-generated profile, based on publicly available information

Danijela Stojanovic

Office of Surveillance and Epidemiology, Center for Drug and Evaluation, U.S. Food and Drug Administration , Silver Spring, MD

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 November 2020 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Closed access
PDF file
MMMohamed Mohamoud
Mohamed Mohamoud
CHCasie Horgan
Casie Horgan
EEEfe Eworuke
Efe Eworuke
EDElizabeth Dee
Elizabeth Dee
JBJustin Bohn
Justin Bohn
LGLois La Grenade
Lois La Grenade

17 October 2022 in Epidemiology
Verified
Journal Article
Closed access
ESElizabeth A. Suarez
Elizabeth A. Suarez
MNMichael Nguyen
Michael Nguyen
DZDi Zhang
Di Zhang
YZYueqin Zhao
Yueqin Zhao
DSDanijela Stojanovic
Danijela Stojanovic
JMJudith C. Maro
Judith C. Maro
Background: Traditional surveillance of adverse infant outcomes following maternal medication exposures relies on pregnancy exposure registries, which are often underpowered. We characterize the statistical power of TreeScan, a data mining tool, to identify potential signals in the setting of perinatal medication exposures and infant outcomes. Methods: We used empirical data to inform background incidence of major congenital malformations and other birth conditions. Statistical power was calculated using two probability models compatible with TreeScan, Bernoulli and Poisson, while varying the sample size, magnitude of the risk increase, and incidence of a specified outcome. We also simulated larger referent to exposure matching ratios when using the Bernoulli model in the setting of fixed N:1 propensity score matching. Finally, we assessed the impact of outcome misclassification on power. Results: The Poisson model demonstrated greater power to detect signals than the Bernoulli model across all scenarios and suggested a sample size of 4,000 exposed pregnancies is needed to detect a twofold increase in risk of a common outcome (approximately 8 per 1,000) with 85% power. Increasing the fixed matching ratio with the Bernoulli model did not reliably increase power. An outcome definition with high sensitivity is expected to have somewhat greater power to detect signals than an outcome definition with high positive predictive value. Conclusions: Use of the Poisson model with an outcome definition that prioritizes sensitivity may be optimal for signal detection. TreeScan is a viable method for surveillance of adverse infant outcomes following maternal medication use.

24 July 2024 in American Journal of Epidemiology
Verified
Journal Article
Closed access
PDF file
CHCasie E Horgan
Casie E Horgan
JBJillian Burk
Jillian Burk
EEEfe Eworuke
Efe Eworuke
DSDanijela Stojanovic
Danijela Stojanovic
JLJennifer G Lyons
Jennifer G Lyons
JMJudith C Maro
Judith C Maro
We conducted retrospective public health surveillance using data from 2006 to 2016 in 7 integrated delivery systems from the US Food and Drug Administration’s Sentinel System. We identified pediatric hypertensive patients by clinical and claims-based definitions and compared demographics, baseline profiles, and follow-up time profiles. Among 3 757 803 pediatric patients aged 3 to 17 years, we identified 781 722 children and 551 246 teens with at least 3 blood pressure measurements over 36 months. Of these, 70 315 children (9%) and 47 928 teens (8.7%) met the clinical definition for hypertension, and 22 465 (2.8%) children and 60 952 (11%) of teens met the clinical definition for elevated, nonhypertensive blood pressure. Of the 3.7 million patients, we identified 3246 children and 7293 teens with any claim for hypertension (claims definition). Evidence of hypertension claims among those meeting our clinical definition was poor; 2.2% and 7.3% of clinically hypertensive children and teens had corresponding claims for hypertension. Baseline profiles for patients with claims-based hypertension suggest greater severity of disease compared with clinical patients. Claims-based patients had higher rates of all-cause mortality during follow-up. Pediatric hypertension in claims-based data sources is under-captured but may serve as a marker for greater disease severity. Investigators should understand coding practices when selecting real-world data sources for pediatric hypertension work.


6 September 2026 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
DSDanijela Stojanovic
Danijela Stojanovic
LWLisa Wolf
Lisa Wolf
MRM. Stacey Ricci
M. Stacey Ricci
MMMonica A. Muñoz
Monica A. Muñoz
Accurate identification of medicines used in adverse event reports is crucial for effective postmarketing safety surveillance. The US Food and Drug Administration's (FDA) four‐letter suffix naming convention was designed to facilitate accurate biological product identification, but the extent to which these suffixes have been incorporated into biosimilar reporting remains unclear. We conducted a cross‐sectional analysis of US adverse event reports for all 72 FDA‐approved biosimilar products in the FDA Adverse Event Monitoring System (AEMS) received through August 31, 2025, evaluating the proportion of reports containing a four‐letter suffix, proprietary name, or other manufacturer identifiers. Of 24,711 reports analyzed, 12.7% ( n = 3126) contained a biosimilar suffix, whereas 98.2% ( n = 24,264) contained a proprietary name and 82% reported the manufacturer name. Suffixes served as the sole product identifier in only 1.7% ( n = 413). These suffix‐only reports were distinct: more frequently submitted directly to FDA (86.2% vs. 15.0%), by healthcare professionals (73.3% vs. 59.0%), commonly originated from Veterans Affairs Medical Centers and specialty pharmacies and involved more serious outcomes (47.7% vs. 27.9%), suggesting certain organizational preferences favoring nonproprietary name reporting. The product distribution also differed, with adalimumab‐aacf most common in suffix‐only reports (18.9%) vs. infliximab‐dyyb overall (21.1%). Manufacturer information was present in 42.6% of suffix‐only reports. These results suggest FDA's nonproprietary naming convention has achieved limited implementation for biosimilars in AEMS reporting practices, and other information present in AEMS reports may be sufficient for accurately identifying biosimilar products.